New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DVAX;BRCM;BA;CLNE;DKS;SODA;EXEL;CSCO;WPRT;GILD;HD;SAND;O;QCOM;GE;CELG From The Last 14 Days
Check below for free stories on DVAX;BRCM;BA;CLNE;DKS;SODA;EXEL;CSCO;WPRT;GILD;HD;SAND;O;QCOM;GE;CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 10, 2014
09:03 EDTGEGE to provide grid modernization solutions to Furnas
GEís Digital Energy business is providing Furnas and Triangulo Mineiro Transmissora/Geoenergia with the latest in protection and control equipment to ensure performance and quality for each of the utilityís grid modernization projects. Furnas is one of the biggest utilities in Latin America and is responsible for power transmission in south, southeast and mid west Brazil. These projects, which support the modernization of Brazilís grid, mark GEís entry into Brazilís ANEEL transmission auctions. The auctions were won in December 2013 by TMT, a collaborative utility composed of Furnas and FIP Milao, with Furnas being the largest participant at 49%.
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
07:24 EDTGILDInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
06:07 EDTCLNEClean Energy supplies Hawaii Gas with first LNG shipment
Subscribe for More Information
05:37 EDTGILDGilead announces Phase 2 results for investigational sofosbuvir-based regimens
Gilead Sciences announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, for the treatment of chronic hepatitis C virus, or HCV, infection. The first study, ELECTRON2, is an ongoing, open-label Phase 2 clinical trial evaluating a once-daily fixed-dose combination of SOF 400 mg and the NS5A inhibitor ledipasvir, or LDV, 90 mg, with and without ribavirin, or RBV, twice-daily, among HCV-infected patient populations. In this study, 100% of treatment-naÔve genotype 3 patients receiving 12 weeks of LDV/SOF plus RBV and 64% of treatment-naÔve genotype 3 patients receiving 12 weeks of LDV/SOF without RBV achieved a sustained virologic response 12 weeks after completing therapy. Among genotype 1-infected patients who had failed prior treatment with SOF plus RBV, 100% achieved SVR12 following 12 weeks of LDV/SOF plus RBV. Additionally, 65% of genotype 1-infected patients with decompensated or Child-Turcotte-Pugh Class B cirrhosis receiving 12 weeks of LDV/SOF without RBV achieved SVR12. LDV/SOF with and without RBV was well-tolerated, including among patients with more advanced liver disease. A second study, Study GS-US-342-0102, is an ongoing randomized Phase 2 clinical trial in which treatment-naÔve, non-cirrhotic patients with genotypes 1-6 HCV infection received a 12-week course of SOF plus the pan-genotypic NS5A inhibitor GS-5816. Patients received SOF 400 mg and either GS-5816 25 mg or GS-5816 100 mg. In this study, 94.8% of patients receiving the 25 mg dose of GS-5816 and 96.1% of patients receiving the 100 mg dose achieved SVR12.
05:32 EDTGILDGilead announces results from study of Sovaldi
Subscribe for More Information
April 9, 2014
16:00 EDTGILDOptions Update; April 9, 2014
Subscribe for More Information
13:49 EDTBABoeing, Air Canada sign agreement for Boeing Maintenance Performance Toolbox
Boeing (BA) announced that Air Canada (AIDIF) has signed an agreement to implement the Boeing Maintenance Performance Toolbox to support maintenance operations for its 767, 777, 787 and 737 MAX airplane fleets. The Maintenance Performance Toolbox suite delivers access to information that technicians need to resolve airplane maintenance issues. As part of the Toolbox deployment project, Boeing will also provide services for transition and migration of customized data from maintenance management applications currently used by Air Canada, and will enable integration with existing maintenance resource planning systems.
12:12 EDTCELGMarkman documents appear to favor Celgene, The Street says
Public documents for the pre-trial Markman hearing appear to favor Celgene over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents, The Street's Adam Feuerstein reports. Shares of Celgene are up 5% to $145.33 in mid-day trading. Reference Link
11:51 EDTGILDStocks with call strike movement; AAL GILD
American Airlines (ALL) August 44 call option implied volatility increased 4% to 39, Gilead (GILD) August 80 call option implied volatility decreased 2% to 34 according to IVolatility.
11:43 EDTGILDGilead defended by analysts after recent pullback
Subscribe for More Information
11:40 EDTCSCOCisco to participate in a conference call with Sanford Bernstein
Bernstein Analyst Ferragu hosts a conference call with Cisco's SVP Jiandani to discuss Cisco's Application Centric Infrastructure (ACI) on April 10 at 11 am. Webcast Link
10:37 EDTHDBofA/Merrill's retail/hardline analysts hold an analyst/industry conference call
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
09:20 EDTDKSBofA/Merrill's retail analysts hold an analyst/industry conference call
Subscribe for More Information
09:10 EDTGEWal-Mart to purcahse energy-efficient LED ceiling lighting fixtures from GE
Subscribe for More Information
08:41 EDTGILDAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
07:56 EDTGILDGilead poised for strong earnings, says RW Baird
Subscribe for More Information
07:23 EDTGILDEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use